Announcement • Apr 23
Inogen, Inc. to Report Q1, 2026 Results on May 07, 2026 Inogen, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026 Announcement • Apr 21
Inogen, Inc., Annual General Meeting, Jun 05, 2026 Inogen, Inc., Annual General Meeting, Jun 05, 2026. Announcement • Apr 07
Inogen, Inc. Appoints Vafa Jamali as Class I Independent Director, Effective on the Date of the Company’s 2026 Annual Meeting, or June 15, 2026 Inogen, Inc. announced the appointment of Vafa Jamali as Class I independent director to the Inogen Board of Directors, effective on the date of the Company’s 2026 Annual Meeting, or June 15, 2026 if earlier, with a term expiring at the Company’s 2027 annual meeting of stockholders or until his successor is duly elected and qualified. The Board also appointed Mr. Jamali to the Audit Committee of the Board (the Audit Committee) and the Compliance Committee of the Board (the Compliance Committee), effective as of the Effective Date. Mr. Jamali, 56, served as Chairman and Chief Executive Officer of ZimVie Inc., a medical technology company, from February 2021 to November 2025, where he led the company’s Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability. Previously, Mr. Jamali served as the Chief Commercial Officer of Rockley Photonics, a silicon photonics company, where he led commercial strategic planning for the early-stage company from October 2020 until joining ZimVie. Prior to that, Mr. Jamali served as Senior Vice President and President, Respiratory, Gastrointestinal and Informatics (“RGI”) of Medtronic plc from May 2017 until October 2020. Before leading the RGI business, he served as Senior Vice President and President, Early Technologies of Medtronic plc from January 2016 until May 2017 and prior to that he served as Vice President and General Manager, GI Solutions of Medtronic plc from January 2015 until January 2016. Before joining Medtronic, Mr. Jamali held leadership positions with Covidien plc, Cardinal Health, Inc. and Baxter International Inc. Mr. Jamali currently serves on the board of directors of Baylis Medical Technologies, a private medical device company, and Eptam Plastics, a private medical equipment manufacturer. Mr. Jamali received his Bachelor of Commerce degree with distinction from the University of Alberta in Edmonton, Canada. Announcement • Jan 12
Inogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026 Inogen, Inc. announced that they will report Q4, 2025 results on Feb 24, 2026 Announcement • Jan 07
Inogen, Inc. Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States Inogen, Inc. announced the launch of Aurora CPAP masks, a new product within the expanding Inogen portfolio. Aurora's introduction marks a significant milestone in Inogen's strategy to expand its respiratory care portfolio and now bring quality, high-performing masks to patients indicated for obstructive sleep apnea (OSA). Engineered for superior comfort, reliability, and usability, Aurora Masks establishes Inogen's presence in the growing sleep-therapy market and expands Inogen's addressable market opportunity. The company intends to leverage its existing distribution channels and partnerships to bring Aurora CPAP masks to customers and strengthen relationships with providers. Aurora Masks launch is supported by a patient-use study, in which the majority of patients reported being highly satisfied with the Aurora masks1. The Aurora Mask portfolio--which includes the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows--is specifically designed to meet the diverse needs of most patients using CPAP devices. Aurora Masks provide options for different facial structures and therapy needs, promoting patient-focused care and encouraging consistent use in sleep and respiratory therapy. Key Features: High-Quality Headgear: features a triple-material design with ultrasonic edge sealing technology, promoting comfort and durability. Com comfortable Cushion Design: Medical-grade rebound silicone cushion is soft, airtight, and hypoallergenic - designed to reduce facial pressure and improve patient fit and comfort. Quiet Honeycomb Vent Design: Promotes a peaceful sleep environment for users and partners. Simple Maintenance: Easy to assemble, disassemble, and clean for everyday convenience. Universal Compatibility: Works seamlessly with most CPAP devices. FDA 510(k) Cleared: Meets rigorous safety and performance standards. Aurora CPAP masks are now offered through certified partners. Announcement • Nov 05
Inogen, Inc. Provides Earnings Guidance for Fourth Quarter and Reiterates Revenue Guidance for the Full Year 2025 Inogen, Inc. provided earnings guidance for fourth quarter and reiterated revenue guidance for the full year 2025. For the quarter, the company expects reported revenue in the range of $87 million to $90 million, reflecting approximately 10% year-over-year growth at the midpoint of the range, compared to the Company’s fourth quarter 2024 revenue. For the year, the company is reiterating its reported revenue outlook in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint, when compared to the Company’s 2024 revenue. Announcement • Oct 15
Inogen, Inc. to Report Q3, 2025 Results on Nov 05, 2025 Inogen, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025 Announcement • Sep 26
Inogen, Inc. Appoints Naga Rameswamy as Chief Technology Officer, Effective September 29, 2025 Inogen, Inc. announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. Mr. Rameswamy brings more than two decades of leadership in the medical device industry spanning innovation, R&D, and digital transformation. Prior to Alcon, he spent nearly twenty years at GE Healthcare, culminating as Vice President of Digital Health Engineering. He has advanced secure device connectivity, remote diagnostics, fleet reliability, and care management platforms across diagnostic imaging, ultrasound, and patient monitoring modalities. He has scaled global engineering teams and partnered closely with quality, regulatory, manufacturing, sales, service, and cloud infrastructure to deliver compliant, secure, and intuitive products & solutions that improve serviceability, extend product lifecycles, and enhance experiences for patients, caregivers, and clinicians. Announcement • Aug 08
Inogen, Inc. Provides Earnings Guidance for Third Quarter and Full Year 2025 Inogen, Inc. provided earnings guidance for third quarter and full year 2025. For the quarter, the company expects reported revenue in the range of $91 million to $93 million, reflecting approximately 4% year-over-year growth at the midpoint of the range, relative to the Company’s third quarter 2024 revenue.
For the full year 2025, the company expects reported revenue in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint of the range, relative to the Company’s 2024 revenue. Announcement • Jul 17
Inogen, Inc. to Report Q2, 2025 Results on Aug 07, 2025 Inogen, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Announcement • Jun 24
Inogen, Inc. Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy Inogen, Inc. announced the launch of VoxiTM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. As the latest addition to Inogen's product portfolio, Voxi 5 augments the company's line of portable oxygen concentrators, significantly expanding the market potential while leveraging existing sales channels. The Voxi 5 stationary oxygen concentrator combines affordability with durability, setting a new standard in oxygen therapy. Developed in collaboration with Yuwell Medical, Voxi 5 presents a viable option for patients seeking reliable stationary oxygen therapy, delivering 1-5 L/min of quiet1, pure2, continuous flow oxygen in a compact3 and efficient design. The device also features caster wheels to allow for worry free movement between rooms in the home, providing enhanced mobility and ease-of-use. Voxi 5 complements the Inogen At Home®? product by offering a value-driven solution for price-sensitive customers or those in need of an additional unit for multi-room use. The Voxi 5 further solidifies Inogen's position as a pioneer in the home oxygen therapy market, offering patients and healthcare providers a reliable and efficient solution for managing chronic respiratory conditions. Key Features: Quiet Operation: Promoting a peaceful home environment. Compact Design: Includes lockable casters for ease of movement. 3-Year Sieve Bed Warranty: Providing reliable, long-term performance. Advanced Filtration: Features an 8-layer internal gas pathway for delivering medical-grade oxygen. The Voxi 5 is available for purchase through Inogen's website and authorized partners. Announcement • May 08
Inogen, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025 Inogen, Inc. provided earnings guidance for the second quarter and full year 2025. For the second quarter of 2025, the company expects reported revenue in the range of $89 million to $91 million, reflecting flat to approximately 3% growth, relative to the Company’s second quarter 2024 revenue.
For the full year 2025, the company continues to expect reported revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue. Announcement • Apr 16
Inogen, Inc. to Report Q1, 2025 Results on May 07, 2025 Inogen, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 Announcement • Mar 28
Inogen, Inc., Annual General Meeting, May 14, 2025 Inogen, Inc., Annual General Meeting, May 14, 2025. Announcement • Feb 26
Inogen, Inc. Provides Revenue Guidance for the First Quarter 2025 and Full Year 2025 Inogen, Inc. provided revenue guidance for the first quarter 2025 and full year 2025. For the first quarter 2025, the company expects revenue in the range of $79 million to $81 million, reflecting 1% to 4% reported growth relative to the Company’s first quarter 2024 revenue.
For the full year 2025, company expects revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue. Announcement • Feb 04
Inogen, Inc. Announces Board Changes Inogen, Inc. announced the appointment of Mira Kirti Sahney to Inogen’s Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. Mira Sahney serves as a board member of Claria Medical, a privately held minimally invasive surgical tools company. She joined Claria Medical’s board in 2017. Previously, Ms. Sahney served as the President of the Pelvic Health Operating Unit at Medtronic from 2021 to 2024. Before joining Medtronic, Ms. Sahney served as President, Chief Executive Officer, and Director of Hyalex Orthopaedics, a venture-backed medical device innovator from 2017 to 2021. Prior to Hyalex, she served in leadership roles at Smith + Nephew, including as Senior Vice President and General Manager of both the Ear, Nose and Throat and the Gynecology businesses. She began her medical technology career as co-founder and President of Myomo, Inc., a wearable medical robotics company addressing neurological disorders. Ms. Sahney graduated summa cum laude from the University of Michigan with a B.S. in Mechanical Engineering. She holds an M.S. from Stanford University in Mechanical Engineering. Ms. Sahney also holds both an M.S. in Engineering and an MBA from the Massachusetts Institute of Technology. In connection with the appointment, Ms. Sahney will be joining the Compliance Committee as well as the Nominating and Governance Committee of the Board. Announcement • Jan 27
Inogen, Inc. announced that it expects to receive $27.209763 million in funding from Yuwell (Hong Kong) Holdings Limited Inogen, Inc. announced that it has entered into a securities purchase agreement to issue 2,626,425 shares at a price of $10.36 per share for the gross proceeds pf $10.36 for the total gross proceeds of $27,209,763 on January 25, 2025. The transaction will include participation from Yuwell (Hong Kong) Holdings Limited. The closing of the Private Placement is expected to occur during the first quarter of 2025. Announcement • Dec 31
Inogen, Inc. Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device Inogen, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company's ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S. SIMEOX 200 is the next-generation of the original Simeox (currently available in select international markets). It is intended to promote and improve bronchial drainage by enhancing mobilization of bronchial secretions via high frequency oscillatory vibrations and intermittent negative pressure to the airway during exhalation. The device is intended to be prescribed for use in patients capable of independently generating cough. SIMEOX 200 is predominantly aimed to help patients with chronic lung diseases associated with mucus hypersecretion and mucus retention, such as Bronchiectasis, COPD (Chronic Obstructive Pulmonary Diseases), Cystic Fibrosis or Primary Ciliary Dyskinesia. Traditional airway clearance therapies can be time consuming and constraining with mixed results. SIMEOX 200 provides an innovative alternative, delivering efficient bronchial drainage, specifically in low lung volumes, that can be administered in healthcare centers and institutions, as well as at home. Inogen plans to pursue a limited launch of SIMEOX 200 in targeted sites in 2025. New Risk • Nov 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$34m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Reported Earnings • Nov 09
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$1.97 loss in 3Q 2023) Third quarter 2024 results: US$0.25 loss per share (improved from US$1.97 loss in 3Q 2023). Revenue: US$88.8m (up 5.8% from 3Q 2023). Net loss: US$5.96m (loss narrowed 87% from 3Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Announcement • Nov 08
Inogen, Inc. Provides Revenue Guidance for the Full Year 2024 Inogen, Inc. provided revenue guidance for the full year 2024. The company expects revenue for the full year 2024 to range from approximately $329 million to $331 million, which represents approximately 4% to 5% growth over the Company’s prior year revenue. Announcement • Oct 17
Inogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Inogen, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024 Announcement • Oct 09
Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting Poc Inogen, Inc. announced that it has commenced the U.S. market release of the Inogen® Rove 4™ Portable Oxygen Concentrator. With an additional, fourth flow setting delivering up to 840ml/min of medical grade oxygen, in a lightweight user-friendly design of less than 3 lbs and three battery configurations providing up to 5 hours and 45 minutes of operation, the versatility of Rove 4 empowers patients with choices that may help them with normal activities of daily living. The Rove 4 utilizes Inogen’s patented pulse-dose Intelligent Delivery Technology. This technology provides unparalleled triggering sensitivity to quickly detect a breath and deliver oxygen within the first 250 milliseconds of the inspiration, where oxygen has the most effect on lung gas exchange. Designed for reliability, the Rove 4 offers a best-in-class expected service life of up to 8 years. New Risk • Aug 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$40m net loss in 2 years). Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Significant insider selling over the past 3 months (€79k sold). New Risk • Aug 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$45m net loss in 2 years). Significant insider selling over the past 3 months (€79k sold). Reported Earnings • Aug 07
Second quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 2Q 2023) Second quarter 2024 results: US$0.24 loss per share (improved from US$0.42 loss in 2Q 2023). Revenue: US$88.8m (up 6.1% from 2Q 2023). Net loss: US$5.59m (loss narrowed 43% from 2Q 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 20 percentage points per year, which is a significant difference in performance. Announcement • Aug 07
Inogen, Inc. Provides Revenue Guidance for the Full Year 2024 Inogen, Inc. provided revenue guidance for the full year 2024. The company expects revenue for the full year 2024 to range from approximately $325 million to $330 million, which represents approximately 3% to 5% growth over the Company’s prior year revenue. Announcement • Jul 16
Inogen, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Inogen, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024 Announcement • Jul 04
Inogen, Inc. Appoints Kevin P. Smith as General Counsel and Executive Vice President, Business Development, Effective July 22, 2024 Inogen, Inc. announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith joins Inogen from Sirtex Medical, where he served as General Counsel and Executive Vice President, Business Development, since 2018. Mr. Smith brings nearly thirty years of experience to the Company. Prior to joining Sirtex, Kevin served as vice president and associate general counsel at Flexion Therapeutics, focusing on securities requirements, business development, and intellectual property. Previously, he was general counsel for the Danaher Life Sciences Platform. He has also held senior legal leadership positions within Novartis Pharmaceuticals. Before moving in-house, Mr. Smith worked for multinational law firms in New York, Silicon Valley, and London. Announcement • Jun 05
Inogen, Inc. Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Survival and Increased Cost-Effectiveness Ratio Inogen, Inc. shared the results of a study published in the journal Pulmonary Therapy, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies. The study sourced data from the French national healthcare system database, the Systeme National des Donnees de Sante (SNDS). With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date. The results showed that portable oxygen concentrator (POC) use, either alone or in combination with other oxygen modalities, was associated with improved survival and similar healthcare resource use, such as hospitalizations and specialist visits, compared to stationary concentrators, compressed tanks and liquid oxygen. Additionally, based on the incremental cost-effectiveness ratio (ICER), POCs were cost-effective compared to stationary concentrators, compression tanks, and liquid oxygen. In a secondary analysis of the POC group, two sub-groups were classified based on device autonomy i.e. higher mobility and lower mobility groups. Within the POC group, the higher mobility POC sub-group were associated with better survival, lower healthcare resource use and lower related costs vs the lower mobility POC sub-group. Recent Insider Transactions • May 15
Executive VP recently sold €79k worth of stock On the 10th of May, Jason Somer sold around 10k shares on-market at roughly €7.95 per share. This transaction amounted to 69% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • May 08
First quarter 2024 earnings released: US$0.62 loss per share (vs US$0.88 loss in 1Q 2023) First quarter 2024 results: US$0.62 loss per share (improved from US$0.88 loss in 1Q 2023). Revenue: US$78.0m (up 8.1% from 1Q 2023). Net loss: US$14.6m (loss narrowed 28% from 1Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance. Announcement • May 08
Inogen, Inc. Provides Revenue Guidance for the Second Quarter of 2024 Inogen, Inc. provided revenue guidance for the second quarter of 2024. For the second quarter of 2024, the company expects revenue to be in the range of $81 million to $84 million. New Risk • Apr 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$45m net loss in 3 years). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Announcement • Apr 20
Inogen, Inc., Annual General Meeting, Jun 05, 2024 Inogen, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 Pacific Standard Time. Agenda: To elect two Class I directors from the nominees described in this proxy statement; to ratify the appointment of Deloitte & Touche LLP as company independent registered public accounting firm for fiscal year ending December 31, 2024; to approve, on an advisory and non-binding basis, executive compensation as described in this proxy statement; to approve the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. Announcement • Apr 11
Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024 Inogen, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024 Announcement • Feb 29
Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024 Inogen, Inc. provided earnings guidance for the first quarter 2024. For the period, the company expects revenue of $73 to $74 million, reflecting 1% to 3% reported growth relative to the first quarter 2023. Reported Earnings • Feb 28
Full year 2023 earnings released: US$4.42 loss per share (vs US$3.67 loss in FY 2022) Full year 2023 results: US$4.42 loss per share (further deteriorated from US$3.67 loss in FY 2022). Revenue: US$315.7m (down 16% from FY 2022). Net loss: US$102.4m (loss widened 22% from FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Announcement • Jan 31
Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Inogen, Inc. announced that they will report Q4, 2023 results After-Market on Feb 27, 2024 Announcement • Jan 05
Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer On January 2, 2024, the Board of Directors (Board) of Inogen, Inc. appointed Grgoire Ramade to serve as Chief Commercial Officer (CCO) of the Company, effective January 2, 2024. Most recently, Mr. Ramade, 54, served as the company's Senior Vice President of International Sales from November 2023. Prior to joining the company, Mr. Ramade served as Senior Vice President and Chief Commercial Officer of Vapotherm, Inc. from October 2020 to October 2023 and as Vice President, International Sales and Worldwide Marketing of Vapotherm, Inc. since May 2016. Mr. Ramade worked at Becton Dickinson Medical-Pharmaceutical Systems as Vice President of Global Marketing and Business Development from January 2013 to May 2016. He also held the positions of Senior Marketing Director Home Healthcare Solution at Philips Healthcare from 2010 to 2012, Marketing Director EMEA at Philips Respironics from 2005 to 2009 and Product Manager of Consumable Masks and Accessories at Philips Respironics from 2004 to 2005. Mr. Ramade holds a bachelors degree in International Business with a minor in Economics from the American University of Paris and an MBA in International Business and Marketing from the Ecole Nationale des Ponts et Chausses School of International Management. Announcement • Nov 29
Inogen, Inc. Announces Separation Agreement with Nabil Shabshab Inogen, Inc. announced Nabil Shabshab Separation Agreement; Resignation as a Director. The company announced dated November 10, 2023, Mr. Shabshab’s role as an officer and employee of the Company ended effective November 10, 2023. Reported Earnings • Nov 10
Third quarter 2023 earnings released: US$1.97 loss per share (vs US$0.41 loss in 3Q 2022) Third quarter 2023 results: US$1.97 loss per share (further deteriorated from US$0.41 loss in 3Q 2022). Revenue: US$84.0m (down 20% from 3Q 2022). Net loss: US$45.7m (loss widened 381% from 3Q 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. New Risk • Oct 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.4m (US$97.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Market cap is less than US$100m (€92.4m market cap, or US$97.6m). Announcement • Oct 11
Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Inogen, Inc. announced that they will report Q3, 2023 results After-Market on Nov 07, 2023 Reported Earnings • Aug 08
Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 loss in 2Q 2022) Second quarter 2023 results: US$0.42 loss per share (further deteriorated from US$0.15 loss in 2Q 2022). Revenue: US$83.6m (down 19% from 2Q 2022). Net loss: US$9.83m (loss widened 186% from 2Q 2022). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Announcement • Aug 08
Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United States Inogen, Inc. announced the introduction of the Rove 6(TM) portable oxygen concentrator in the United States with best in class 8-year expected service life. The Inogen(R) Rove 6(TM) was launched in Europe in December 2022. Having completed the necessary regulatory processes, the expected service life of the Rove 6 will be extended from 5 years to 8 years for all Rove 6 devices sold worldwide. The 8 year best-in-class expected service life has also been extended to Inogen One(R) G5 portable oxygen concentrators in the US. The Inogen®? Rove 6(TM) is a 6-setting portable oxygen concentrator that also provides the longest battery life of any portable oxygen concentrator currently available on the market. This device delivers up to 1,260 mL/minute of medical grade oxygen at a weight of only 4.8 pounds. The Inogen(R") Rove 6(TM) is available with two battery options, including an extended battery that can support a battery life up to 12 hours and 45 minutes. Announcement • Aug 02
Inogen, Inc. Announces Board Changes Inogen, Inc. and George Parr, Executive Vice President and Chief Commercial Officer of the Company, mutually determined that Mr. Parr would separate from the Company on or before July 31, 2023. On an interim basis, Nabil Shabshab, President and Chief Executive Officer, will manage the commercial and marketing teams to drive the Company forward and ensure business continuity during this transition period. Announcement • May 07
Inogen, Inc. Reiterates Earnings Guidance for the Year 2023 Inogen, Inc. reiterated earnings guidance for the year 2023. The company expects total company revenue for the full year 2023 to grow in the low to mid digits. The company remains focused on its return to profitability by the fourth quarter of 2023. Reported Earnings • May 06
First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.63 loss in 1Q 2022) First quarter 2023 results: US$0.88 loss per share (further deteriorated from US$0.63 loss in 1Q 2022). Revenue: US$72.2m (down 10% from 1Q 2022). Net loss: US$20.3m (loss widened 43% from 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 26
Full year 2022 earnings released: US$3.67 loss per share (vs US$0.28 loss in FY 2021) Full year 2022 results: US$3.67 loss per share (further deteriorated from US$0.28 loss in FY 2021). Revenue: US$377.2m (up 5.4% from FY 2021). Net loss: US$83.8m (loss widened US$77.4m from FY 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Announcement • Feb 11
Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023 On February 6, 2023, Inogen, Inc. (the “Company”) and Bart Sanford, Executive Vice President, Operations of the Company, mutually determined that Mr. Sanford would separate from the Company on or before March 1, 2023. In connection with Mr. Sanford’s separation as Executive Vice President, Operations, Mr. Sanford and the Company entered into a transition agreement and release, whereby Mr. Sanford agreed to provide transition services to the Company in his current role until, at the latest, March 1, 2023. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 03
Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.54 profit in 3Q 2021) Third quarter 2022 results: US$0.41 loss per share (down from US$0.54 profit in 3Q 2021). Revenue: US$105.4m (up 13% from 3Q 2021). Net loss: US$9.51m (down 178% from profit in 3Q 2021). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Announcement • Nov 03
Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 Inogen, Inc. provided revenue guidance for the fourth quarter of 2022. The company now projects revenue for the fourth quarter of 2022 to be in the range of approximately $87 million to $92 million, or approximately 14% to 20% growth year-over-year. Announcement • Oct 06
Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Inogen, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 02, 2022 Reported Earnings • Aug 06
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.23 profit in 2Q 2021) Second quarter 2022 results: US$0.15 loss per share (down from US$0.23 profit in 2Q 2021). Revenue: US$103.4m (up 1.8% from 2Q 2021). Net loss: US$3.44m (down 168% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance. Board Change • Aug 06
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Jul 09
Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Inogen, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 04, 2022 Announcement • May 19
Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022 Inogen, Inc. announced the appointment of Agnes Lee to the position of Senior Vice President of Investor Relations and Strategic Planning, effective May 23, 2022. Agnes joins Inogen from Butterfly Network, where she served as Vice President of Investor Relations. Prior to Butterfly, she led proactive investor relations programs at Fluidigm and ResMed, Inc. Board Change • Apr 27
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 22
Inogen, Inc., Annual General Meeting, Jun 08, 2022 Inogen, Inc., Annual General Meeting, Jun 08, 2022, at 10:00 Pacific Standard Time. Agenda: To elect three Class II directors from the nominees described in the proxy statement; to ratify the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; to approve, on an advisory and non-binding basis, executive compensation as described in this proxy statement; and to transact other business that may properly come before the Annual Meeting, or any adjournments or postponements thereof. Announcement • Apr 20
Inogen, Inc. Announces Management Changes Inogen, Inc. announced that this Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of Inogen, Inc. (the “Company”) dated March 22, 2022 and filed with the Commission on March 23, 2022 (the “Original Form 8-K”), which disclosed the appointment of each of Kevin King, Mary Kay Ladone, and Glenn Boehnlein to the Board of Directors of the Company (the “Board”), effective March 22, 2022. At the time of filing of the Original Form 8-K, as disclosed in the Original Form 8-K, the Board appointed Mr. King as a member of the Audit Committee of the Board (the “Audit Committee”) and chairperson of the Compensation Committee of the Board (the “Compensation Committee”), Ms. Ladone as a member of the Audit Committee and the Compensation Committee, and Mr. Boehnlein as chairperson of the Audit Committee. At the time of filing the Original Form 8-K, no determination had been made with respect to the appointment of any such directors to the Compliance Committee of the Board (the “Compliance Committee”). This Amendment is being filed solely to report that on April 14, 2022, upon the recommendation of the Nominating and Governance Committee of the Board, the Board appointed Mr. Boehnlein to the Compliance Committee, effective immediately. Effective upon such appointment, the members of the Compliance Committee are Elizabeth Mora (Chair), Kristen Miranda, and Glenn Boehnlein. Announcement • Apr 15
Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022 Inogen, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022 Board Change • Apr 02
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 26
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.28 loss per share (down from US$0.27 loss in FY 2020). Revenue: US$358.0m (up 16% from FY 2020). Net loss: US$6.33m (loss widened 8.6% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 4.0%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Announcement • Jan 30
Loren McFarland Not to Stand for Re-Election as Director of Inogen, Inc On January 6, 2022, Loren McFarland informed Inogen, Inc. that he will not stand for re-election at the Company’s 2022 annual meeting of stockholders. Announcement • Jan 12
Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021 Inogen, Inc. provided preliminary unaudited revenue guidance for the three-month and twelve-month periods ended December 31, 2021. For the three months, the company expects revenue to be in the range of $75.9 to $76.9 million, up 2.6% to 3.9% from the same period in 2020.For the year, the company expects revenue to be in the range of $357.5 to $358.5 million, up 15.9% to 16.2% from 2020. Reported Earnings • Nov 07
Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.077 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$93.1m (up 25% from 3Q 2020). Net income: US$12.2m (up US$13.9m from 3Q 2020). Profit margin: 13% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 05
Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.12 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$101.6m (up 42% from 2Q 2020). Net income: US$5.10m (up 98% from 2Q 2020). Profit margin: 5.0% (up from 3.6% in 2Q 2020). Announcement • May 05
Inogen, Inc. Unable to Provide Guidance for the Full Year 2021 Because of the uncertainties related to the COVID-19 pandemic, Inogen, Inc. is still unable to provide guidance for the full year 2021. Given the uncertain scope and duration of the COVID-19 pandemic, the Company is unable to estimate the related impact on its financial results, including revenue, net income or loss estimates for such period.